Cancer stem cells (CSCs) are responsible for carcinogenesis and tumorigenesis and are involved in drug and radiation resistance, metastasis, tumor relapse and initiation. According to market research study published by Publisher, the global stem cell treatments for cancer market stood at around USD 2,074 million in 2021 and is projected to rise to a worth of USD 4,529 million by 2028 end, thereby garnering a CAGR of 11.8% during 2022-2028. The report provides in-depth analysis and insights regarding the current global market scenario, latest trends and drivers into global stem cell treatments for cancer market. It offers an exclusive insight into various details such as market size, key trends, competitive landscape, growth rate and market segments. This study also provides an analysis of the impact of the COVID-19 crisis on the stem cell treatments for cancer industry. This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the cancer type, and region. The global market for stem cell treatments for cancer can be segmented by cancer type: bone cancer, brain cancer, breast cancer, colorectal cancer, leukemia, lung cancer, melanoma, others. In 2021, the breast cancer segment made up the largest share of revenue generated by the stem cell treatments for cancer market. Stem cell treatments for cancer market is further segmented by region: Asia Pacific, Europe, North America, Rest of the World (RoW). North America was the largest contributor to the global stem cell treatments for cancer market in 2021. By cancer type: - bone cancer - brain cancer - breast cancer - colorectal cancer - leukemia - lung cancer - melanoma - others By region: - Asia Pacific - Europe - North America - Rest of the World (RoW) The report explores the recent developments and profiles of key vendors in the Global Stem Cell Treatments for Cancer Market, including apceth Biopharma GmbH, Benitec Biopharma Ltd., BioNTech SE, Caladrius Biosciences, Inc., Celgene Corporation, ExCellThera Inc., Fluxion Biosciences, Inc., Gamida-Cell Ltd, Genexine, Inc., ImmunoCellular Therapeutics, Ltd., OncoCyte Corporation, OncoMed Pharmaceuticals, Inc., Pluristem Therapeutics Inc., SELLAS Life Sciences Group, Inc., Sphere Fluidics Limited, ViaCyte, Inc., among others. *REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES Historical & Forecast Period This research report provides analysis for each segment from 2018 to 2028 considering 2021 to be the base year. Scope of the Report - To analyze and forecast the market size of the global stem cell treatments for cancer market. - To classify and forecast the global stem cell treatments for cancer market based on cancer type, region. - To identify drivers and challenges for the global stem cell treatments for cancer market. - To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global stem cell treatments for cancer market. - To identify and analyze the profile of leading players operating in the global stem cell treatments for cancer market. Why Choose This Report - Gain a reliable outlook of the global stem cell treatments for cancer market forecasts from 2022 to 2028 across scenarios. - Identify growth segments for investment. - Stay ahead of competitors through company profiles and market data. - The market estimate for ease of analysis across scenarios in Excel format. - Strategy consulting and research support for three months. - Print authentication provided for the single-user license.